The litigation, Mazzarino v. ADMA Biologics, Inc., claims that the company and its top executives misled shareholders by concealing material information throughout the specified period. Plaintiffs allege that ADMA utilized channel stuffing to artificially inflate revenue figures and failed to maintain necessary internal controls over its operations. Furthermore, the suit points to an undisclosed related-party transaction as a primary driver for the allegedly false statements regarding the firm's business health and prospects.
In section Releases
ADMA Biologics Shareholders Face August Deadline in Securities Lawsuit
Investors who lost more than $100,000 in ADMA Biologics stock between August 2024 and March 2026 have until August 10 to file for lead plaintiff status. The class action lawsuit, currently pending in the U.S. District Court for the District of New Jersey, targets alleged federal securities law violations.
Legal representatives at Kahn Swick & Foti, LLC are currently reviewing the claims on behalf of affected shareholders. Those who acquired ADMA securities during the window of August 9, 2024, through March 25, 2026, are encouraged to evaluate their legal options before the upcoming court-imposed deadline. Detailed information regarding the case and registration for potential recovery efforts are available through the ClaimsFiler portal.
Comments (0)
No comments yet. Be the first!